Damoctocog alpha pegol

Damoctocog alfa pegol, nke ana-ere n'okpuru aha Jivi bụ ọgwụ ngwako ọnụ nke eji agwọ hemofilia

Mmetụta ndị ana-ahụkarị na-agụnye isi ọwụwa, ụkwara, agbọ onunu na ahụ ọkụ.

A kwadoro Damoctocog alfa pegol (ihe na-emegide ọbara mgbali elu- recombinant pegylated-aucl) maka iji ọgwụ na United States n'ọnwa Ọgọstụ 2018, na European Union na Nọvemba 2018.^[1]^[2]

Etu esi anụ ọgwụ

Na United States, a na-egosi damoctocog alfa pegol maka iji ya mee ihe na ndị okenye na ndị nọ n'afọ iri na ụma (afọ iri na abụọ ma ọ bụ karịa) nwere hemophilia A (nchaghị nke Factor VIII) maka: (1) Ọgwụgwọ na njikwa nke ọbara ọgbụgba; (2) Nchịkwa oge nke ọbara ọwụwa; (3) Mgbochi usoro iji belata ugboro ole ọbara ọgbụrụ.^[1]

Na ngalaba irope, ana egosi na ọgwụ damoctocog alfa pegol bu na maka ọgwụgwọ na mgbochi nke ọbara ọgbụgba na ndị a gwọrọ n'oge gara aga na haemophilia A (ihe ọmụmụ nke asatọ).

Edensibia

↑ ^1.0 ^1.1 Jivi. U.S. Food and Drug Administration (FDA) (29 August 2018). Retrieved on 1 October 2020.
↑ (July 2019) "Damoctocog Alfa Pegol: A Review in Haemophilia A". Drugs 79 (10): 1147–1156. DOI:10.1007/s40265-019-01152-7. PMID 31218660.

Njikọ ndị ọzọ

Damoctocog alfa pegol. Drug Information Portal. U.S. National Library of Medicine.
Clinical trial number NCT01184820 for "Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration" at ClinicalTrials.gov
Clinical trial number NCT01580293 for "A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A (PROTECT-VIII)" at ClinicalTrials.gov
Clinical trial number NCT01775618 for "Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A" at ClinicalTrials.gov

[Jivi_FDA-1] 1.0 ^1.1 Jivi. U.S. Food and Drug Administration (FDA) (29 August 2018). Retrieved on 1 October 2020.

[Paik_2019-2] (July 2019) "Damoctocog Alfa Pegol: A Review in Haemophilia A". Drugs 79 (10): 1147–1156. DOI:10.1007/s40265-019-01152-7. PMID 31218660.

[1]

[2]